Related references
Note: Only part of the references are listed.Trial of Psilocybin versus Escitalopram for Depression
Robin Carhart-Harris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder A Randomized Clinical Trial
Alan K. Davis et al.
JAMA PSYCHIATRY (2021)
Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels
Martin K. Madsen et al.
NEUROPSYCHOPHARMACOLOGY (2019)
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
R. L. Carhart-Harris et al.
PSYCHOPHARMACOLOGY (2018)
Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults
Randall T. Brown et al.
CLINICAL PHARMACOKINETICS (2017)
Psychedelics in the treatment of unipolar mood disorders: a systematic review
James J. H. Rucker et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
Roland R. Griffiths et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial
Stephen Ross et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
Robin L. Carhart-Harris et al.
LANCET PSYCHIATRY (2016)
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Michael P. Bogenschutz et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2015)
Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction
Matthew W. Johnson et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2014)
Sample size requirements to estimate key design parameters from external pilot randomised controlled trials: a simulation study
M. Dawn Teare et al.
TRIALS (2014)
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Charles S. Grob et al.
ARCHIVES OF GENERAL PSYCHIATRY (2011)
The administration of psilocybin to healthy, hallucinogen-experienced volunteers in a mock-functional magnetic resonance imaging environment: a preliminary investigation of tolerability
Robin L. Carhart-Harris et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2011)
Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
M. Herdman et al.
QUALITY OF LIFE RESEARCH (2011)
Psychedelics and the Human Receptorome
Thomas S. Ray
PLOS ONE (2010)
A Multidimensional Tool to Quantify Treatment Resistance in Depression: The Maudsley Staging Method
Abebaw Fekadu et al.
JOURNAL OF CLINICAL PSYCHIATRY (2009)
The behavioral pharmacology of hallucinogens
William E. Fantegrossi et al.
BIOCHEMICAL PHARMACOLOGY (2008)
Development and reliability of a structured interview guide for the Montgomery Depression Rating Scale (SIGMA)
Janet B. W. Williams et al.
BRITISH JOURNAL OF PSYCHIATRY (2008)
Human hallucinogen research: guidelines for safety
M. W. Johnson et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2008)
Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder
Francisco A. Moreno et al.
JOURNAL OF CLINICAL PSYCHIATRY (2006)
A brief measure for assessing generalized anxiety disorder -: The GAD-7
Robert L. Spitzer et al.
ARCHIVES OF INTERNAL MEDICINE (2006)
The 16-item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): A psychometric evaluation in patients with chronic major depression
AJ Rush et al.
BIOLOGICAL PSYCHIATRY (2003)
The Work and Social Adjustment Scale: a simple measure of impairment in functioning
JC Mundt et al.
BRITISH JOURNAL OF PSYCHIATRY (2002)
Share Paper
